CENTESSA PHARMACEUTICALS-ADR (CNTA) Stock Balance Sheet
USA - NASDAQ:CNTA - US1523091007 - ADR
27.63 USD
-0.37 (-1.32%)
| MRQ (2025-9-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | 50.81M | 383.22M | 128.03M | 393.60M | 595.10M | |||
| Cash Equivalents | null | null | null | null | null | |||
| Cash Due From Banks | null | null | null | null | null | |||
| Investments | null | null | null | null | null | |||
| Net Loans | null | null | null | null | null | |||
| Insurance Receivables | null | null | null | null | null | |||
| Marketable Securities | 195.40M | 98.96M | 128.52M | null | null | |||
| Receivables | 52.21M | 45.30M | 39.15M | 26.70M | 16.80M | |||
| Inventories | null | null | null | null | null | |||
| Other Current Assets | 9.25M | 8.94M | 19.39M | 17.40M | 16.90M | |||
| Total Current Assets | 307.68M | 536.41M | 315.09M | 437.70M | 628.80M | |||
| Non-Current Assets | ||||||||
| PPE Net | 11.19M | 11.76M | 12.95M | 1.20M | 200.00K | |||
| Investments And Advances | 102.83M | null | null | null | null | |||
| Goodwill | null | null | null | null | null | |||
| Intangibles | null | null | null | null | null | |||
| Other Non-Current Assets | 26.61M | 28.63M | 32.20M | 5.40M | 700.00K | |||
| Total Non-Current Assets | 140.63M | 40.39M | 45.15M | 6.60M | 800.00K | |||
| TOTAL ASSETS | 448.30M | 576.80M | 360.25M | 444.30M | 629.60M | |||
| LIABILITIES | ||||||||
| Total Deposits | null | null | null | null | null | |||
| Current Liabilities | ||||||||
| Short Term Borrowings | null | null | null | null | null | |||
| Short Term Debt | 0 | 0 | 0 | 0 | 0 | |||
| Current Portion Of LT Debt. | null | null | null | null | 0 | |||
| Accrued Expenses | 20.38M | 50.02M | 27.46M | 22.90M | 15.80M | |||
| Accounts Payable | 8.68M | 7.14M | 11.81M | 13.80M | 8.10M | |||
| Other Current Liabilities | 55.00K | 835.00K | 112.00K | 1.60M | 800.00K | |||
| Total Current Liabilities | 29.12M | 58.00M | 39.38M | 38.30M | 24.60M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 109.82M | 108.94M | 75.70M | 69.80M | 75.70M | |||
| Deferred Taxes/Income | null | null | null | null | null | |||
| Other Non-Current Liabilities | 7.79M | 8.31M | 8.92M | 0 | 37.70M | |||
| Total Non-Current Liabilities | 117.60M | 117.25M | 84.62M | 69.80M | 113.50M | |||
| TOTAL LIABILITIES | 146.73M | 175.25M | 124.00M | 108.10M | 138.10M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -1.12B | -988.70M | -752.95M | -601.90M | -385.70M | |||
| Additional Paid In Capital | 1.42B | 1.39B | 987.42M | 939.30M | 876.30M | |||
| Minority Interest | null | null | null | null | null | |||
| Common Shares | 364.00K | 359.00K | 273.00K | 300.00K | 300.00K | |||
| Treasury Stock | null | null | null | null | null | |||
| Other Shareholders' Equity | 2.28M | 4.21M | 1.49M | -1.50M | 700.00K | |||
| Shares Outstanding | 134.71M | 132.91M | 98.98M | 95.00M | 90.19M | |||
| Tangible Book Value per Share | 2.2435 | 401.545 | 2.3917 | 3.5464 | 5.4622 | |||
| Total Shareholders' Equity | 301.57M | 401.55M | 236.24M | 336.20M | 491.60M | |||
| TOTAL LIABILITIES AND EQUITY | 448.30M | 576.80M | 360.25M | 444.30M | 629.60M | |||
| Statistics | ||||||||
| Debt/Equity | 0.36 | 0.27 | 0.32 | 0.21 | 0.15 | |||
| Current Ratio | 10.57 | 9.25 | 8.00 | 11.43 | 25.56 | |||
| Return On Assets (ROA) | -54.14% | -40.87% | -41.94% | -48.66% | -60.53% | |||
| Return On Equity (ROE) | -80.48% | -58.71% | -63.95% | -64.31% | -77.52% | |||
All data in USD , ROIC based on taxRate of 0.21